Vancouver, British Columbia — February 13, 2026 — Leads & Copy — Nextleaf Solutions Ltd. has announced the expansion of its Commercial Partners Program™ to support global market growth, highlighted by the completion of an initial softgel shipment to Australia.
In January 2026, Nextleaf (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) served as the exporter of record for a commercial shipment of 756,000 cannabis softgels to a white-label client in Australia. The company is a multi-patented life science company and Canadian cannabis processor.
Vipin Vikraman, VP Operations at Nextleaf Solutions, stated that by leveraging the company’s core capabilities, purchasing scale, lean infrastructure, and established regulatory expertise, Nextleaf streamlined the process and reinforced its role as a disciplined, capital-efficient partner within the global medical cannabis supply chain.
According to Nextleaf, this transaction demonstrates the company’s capabilities as a total quality producer with validated quality assurance systems, multi-site operational coordination, and an export-ready platform.
The company says that international demand for export-ready, pharmaceutical grade product is transitioning from dried cannabis flower to include greater emphasis on derivative products. Nextleaf is advancing its Commercial Partners Program™ to enable increased access to medical cannabis through its formulated ingredients and branded product portfolio.
Nextleaf is aiming to meet rising global demand through patented extraction technology and industry-leading quality, according to CEO Emma Andrews. She believes this sets the standard for processing cannabis at-scale.
The company’s high purity and full spectrum cannabinoid ingredients and dose-controlled drug delivery formats include cannabis softgels, vapes, and oils, through their flagship brand and Canadian market leaders, Glacial Gold.
The company said ready-to-consume, discreet, and non-combustible products offer a reliable, convenient and safe consumption experience for the enhanced confidence of patients and prescribers alike.
The Australian Medicinal Cannabis Association will host their annual conference “United in Compassion’ February 26-28, 2026, in Brisbane, Australia. CEO Emma Andrews will be attending the AMCA conference and is available for meetings in Sidney, Melbourne, and Brisbane.
Australia’s medical cannabis market continues to demonstrate strong growth, supported by a robust regulatory framework, increasing patient adoption, and rising demand for consistent, pharmaceutical-grade formulations. As the market evolves, it has transitioned into a more structured and compliance-driven ecosystem where reliable supply, validated products, and operational discipline are increasingly valued by distributors and prescribers.
According to the release, Nextleaf maintains end-to-end controls and oversight across sourcing, extraction, distillation, formulation, and finished goods through a multi-patented, highly automated, closed-loop system. Nextleaf holds 19 U.S. patents and over 75 patents globally covering advanced cannabinoid processing, including extraction, distillation, and acetylation.
Nextleaf’s house of brands includes a range of value-driven and soft-premium offerings through category-leading flagship brand Glacial Gold, High Plains Cannabis, and recently launched Yard Cannabis.
The global medical cannabis market size reached USD 39.6 billion in 2025, and the market is projected to reach USD 74.3 billion by 2034 (6.9% growth)1.
Australian-based medical cannabis resellers, distributors, and prospective international partners are encouraged to contact Andrews directly through LinkedIn, or through email info@nextleafsolutions.com.
Nextleaf trades as OILS on the Canadian Securities Exchange, OILFF on the OTCQB Market in the United States, and L0MA on the Frankfurt Stock Exchange.
Nextleaf® is a Canadian, federally licensed cannabis processor and life science company, delivering a portfolio of high purity cannabinoid ingredients and branded derivative products at scale. Distributed coast-to-coast across medical and recreational channels, with an emerging niche amongst wellness consumers, Nextleaf’s portfolio includes GMP-compliant and export-ready pharma-grade ingredients and products.
Source: Nextleaf Solutions Ltd.
